Gastric Inhibitory Peptide (human) (trifluoroacetate salt) (Synonyms: GIP (human), Glucose-dependent Insulinotropic Peptide (human)) |
| カタログ番号GC43737 |
胃抑制ペプチド（GIP）は、グルコースに対する反応でインスリン分泌を誘発する内因性の42アミノ酸ペプチドインクレチンホルモンです。
Products are for research use only. Not for human use. We do not sell to patients.
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Gastric inhibitory peptide (GIP) is an endogenous 42-amino acid peptide incretin hormone that induces insulin secretion in response to glucose. It belongs to the secretin/glucagon superfamily of peptides, which includes secretin , glucagon , glucagon-like peptide-1 , GLP-2 , and pituitary adenylate cyclase-activating polypeptide . GIP is a GIP receptor agonist that binds to rat recombinant GIP receptors expressed in CHO-K1 cells (IC50 = 3.2 nM) and increases cAMP accumulation (EC50 = 377 pM). It stimulates insulin secretion from BRIN-BD11 rat pancreatic β-cells when used at a concentration of 10 nM. GIP (1 pmol/min per 100 g) decreases blood glucose level and increases plasma insulin level in rats following glucose challenge. It also decreases plasma glucose level and increases insulin level in ob/ob mice following glucose challenge when administered at a dose of 25 nmol/kg.
Average Rating: 5 (Based on Reviews and 39 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *